| Literature DB >> 21067606 |
Steven D Arrowsmith1, Joseph Ruminjo, Evelyn G Landry.
Abstract
BACKGROUND: Maternal outcomes in most countries of the developed world are good. However, in many developing/resource-poor countries, maternal outcomes are bleaker: Every year, more than 500,000 women die in childbirth, mostly in resource-poor countries. Those who survive often suffer from severe and long-term morbidities. One of the most devastating injuries is obstetric fistula, occurring most often in south Asia and sub-Saharan Africa. Fistula treatment and care are available in many countries across Africa and Asia, but there is a lack of reliable data around clinical factors associated with the success of fistula repair surgery. Most published research has been retrospective. While these studies have provided useful information about the care and treatment of fistula, they are limited by the design. This study was designed to identify practices in care that could lead to the design of prospective and randomized controlled trials.Entities:
Mesh:
Year: 2010 PMID: 21067606 PMCID: PMC2995487 DOI: 10.1186/1471-2393-10-73
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Respondents
| N | % | |
|---|---|---|
| No. of possible surgeons to contact | 82 | |
| No. of letters of invitation sent | 66 | 80% |
| No. of surgeons who agreed to participate in the study | 49 | 74% |
| No. who returned completed questionnaires | 40 | 82% |
| Asia | 5 | 13% |
| West Africa | 21 | 53% |
| Central/Southern Africa | 4 | 10% |
| East Africa | 10 | 25% |
| Country-national surgeon | 32 | 80% |
| International surgeon | 8 | 20% |
| 18 | 45% | |
| French | 18 | 45% |
| English | 22 | 55% |
Antibiotic Practices for Fistula Surgery
| N | % | |
|---|---|---|
| Aminoglycosides (e.g., gentamicin/tobramycin) | 31 | 78% |
| Quinolones (e.g., ciprofloxacin) | 31 | 78% |
| Second-generation cephalosporins (e.g., cefuroxime) | 15 | 38% |
| Third-generation cephalosporins (e.g., ceftriaxone) | 22 | 55% |
| "Rescue" antibiotics for multi-resistant organisms (e.g., imipenem) | 2 | 5% |
| Market factors: drug availability and hospital budget | 12 | 30% |
| Hospital formulary set by administration | 11 | 28% |
| Ministry of Health's essential drug list | 8 | 20% |
| Donation from partners | 4 | 10% |
| Other | 4 | 10% |
| No response | 1 | 3% |
| For every fistula case | 23 | 58% |
| For selected fistula cases | 14 | 35% |
| Never | 2 | 5% |
| No response | 1 | 3% |
| Recommendations of medical literature | 9 | 23% |
| Surgeon training in vesicovaginal fistula surgery | 9 | 23% |
| Availability | 7 | 18% |
| Personal choice | 5 | 13% |
| Cost | 2 | 5% |
| Does not use prophylactic antibiotics | 1 | 3% |
| Other | 7 | 18% |
* Multiple responses allowed; percentages exceed 100%.
^ Exceeds 100% due to rounding.
Figure 1Length of Prophylactic Antibiotic Use. Description: length of prophylactic use reported by respondents. Y axis: Number of respondents. X axis, Period of use (one dose, for 24 hours, More than 24 hours, other comments).
Role of Catheterization
| Minimum | 12 | |
| Maximum | 20 | |
| Average | 17 | |
| No response | 6 | |
| Standard Foley catheter | 37 | 93% |
| Straight catheter without balloon | 1 | 3% |
| Specialty catheter | 1 | 3% |
| No response | 1 | 3% |
| Closed drainage (catheter attached to closed drainage bag) | 26 | 65% |
| Open drainage (catheter drains into basin, bottle, or bucket) | 12 | 30% |
| No response | 2 | 5% |
| Always | 7 | 18% |
| Sometimes | 6 | 15% |
| Never | 23 | 58% |
| No response | 4 | 10% |
| Always | 5 | 13% |
| Sometimes | 11 | 28% |
| Never | 23 | 58% |
| No response | 1 | 3% |
| Always | 6 | 15% |
| Sometimes | 22 | 55% |
| Never | 10 | 25% |
| No response | 2 | 5% |
| Yes | 15 | 38% |
| Sometimes | 9 | 23% |
| No | 15 | 38% |
| No response | 1 | 3% |
^ Exceeds 100% due to rounding.
Figure 2Duration of Catheter Use by Type of Fistula. Description: duration of catheter use by type of fistula reported by respondents. Y axis: Number of Days Post Surgical Catheterization (minimum/maximum). X Axis: Type of fistula: Simple fistula, Large fistula, Difficult fistula.
Management of Urinary Incontinence after Fistula Repair
| N | % | |
|---|---|---|
| By history and physical examination, including dye test | 29 | 73% |
| By history and physical examination, without dye test | 8 | 20% |
| By urodynamic studies | 1 | 3% |
| No response | 2 | 5% |
| Urethral lengthening | 17 | 43% |
| Bulbocavernosus sling (Browning) | 14 | 35% |
| Bladder neck suspension | 11 | 28% |
| Medial thigh fascio-cutaneous flaps | 3 | 8% |
| Other | 11 | 28% |
| No response | 1 | 3% |
| Pelvic floor exercises | 30 | 75% |
| Anticholinergic medications (buscopan, oxybutinin, etc.) | 21 | 53% |
| Bladder training | 17 | 43% |
| Urethral plugs | 5 | 13% |
| Peri-urethral injection (autologous fat, collagen, microspheres) | 2 | 5% |
| Other | 5 | 13% |
| No response | 3 | 8% |
| Pubovaginal sling surgery | 19 | 48% |
| Bladder neck suspension | 18 | 45% |
| Vaginal tape procedure | 6 | 15% |
| Other | 10 | 25% |
| No response | 2 | 5% |
| Counseling | 28 | 70% |
| Long-term pelvic floor exercises | 22 | 55% |
| Urinary diversion | 14 | 35% |
| Urethral plugs | 7 | 18% |
| Other/comment | 3 | 8% |
* Multiple responses allowed; percentages exceed 100%.
^ Exceeds 100% due to rounding.